Orphan drug privilege in Germany's AMNOG: Why the presumed added benefit is under debate in 2026
Germany's orphan drug privilege under AMNOG is facing potential reform. For orphan drugs, added benefit is initially deemed proven by law. However, subsequent full benefit assessments frequently find that added benefit over the appropriate comparator therapy (zVT) cannot be demonstrated. The debate over abolishing this special provision therefore also concerns the €30 million revenue threshold and the requirements for comparative clinical evidence.
EU Pharmaceutical Reform 2026: New orphan drug market exclusivity rules and implications for market access
The EU pharmaceutical reform reshapes orphan market exclusivity: nine, eleven or four years depending on category, with extensions of up to thirteen years. It also introduces an incentive for comparative clinical evidence, without changing the distinct evidence requirements of the JCA and national benefit assessments.
15 Years of AMNOG: What Ticagrelor and Colchicine Reveal About the Evolution of Benefit Assessment
Ticagrelor was the first active substance to undergo Germany's AMNOG early benefit assessment in 2011. It was assessed again in 2016 for cardiovascular secondary prevention. In the 2026 assessment of colchicine, ticagrelor was among the treatment options within optimised standard therapy. These cases show how standards of care and requirements for clinical evidence evolve, while certain evidence gaps persist.
Lurbinectedin and tarlatamab: What the G-BA benefit assessments reveal after the JCA
The German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) published its benefit assessments of lurbinectedin (Zepzelca) and tarlatamab (Imdylltra) on 1 October 2026. They highlight differences between the European Joint Clinical Assessment (JCA) and Germany's early benefit assessment under AMNOG. Although randomised comparative evidence is available for both treatments, the assessments differ in their consideration of patient-reported outcomes, interpretation of safety findings and handling of methodological uncertainty.
Pembrolizumab (Keytruda) in AMNOG: What the G-BA assessments reveal
Germany's AMNOG benefit assessments of pembrolizumab (Keytruda) illustrate how challenging it can be to assess an established immune checkpoint inhibitor across different oncology indications. Key questions in proceedings before the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) concern the appropriate comparator therapy (zweckmäßige Vergleichstherapie, zVT), biomarker-defined populations, the applicability of clinical trial evidence and patient-relevant endpoints.
Evidence transfer in Germany’s AMNOG assessment: What Selumetinib and G-BA practice show for dossier strategy
Transferring evidence from one population to another may be scientifically plausible and accepted by the European Medicines Agency (EMA) for regulatory purposes. In Germany’s AMNOG early benefit assessment, however, this is not automatically sufficient. The practice of Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) shows that the decisive question is whether the available evidence can also answer the specific German assessment question in the target population. An analysis of 52 AMNOG procedures involving evidence transfer shows recurring patterns. Particularly relevant are the comparability of the treatment setting, the suitability of endpoints and the question of which evidence actually supports the assessment of added benefit.
Germany’s 5% clinical trial threshold from 2027
What changes from 1 January 2027 for Germany’s 5% threshold, the BfArM application procedure and the manufacturer rebate.
Tarlatamab and lurbinectedin: What the first HAS assessments show about the transition from JCA to France
Tarlatamab and lurbinectedin are among the first medicines for which the transition from the European Joint Clinical Assessment (JCA) to assessment by the French HAS can be observed in practice. JCA evidence can inform the French assessment, but the Transparency Committee applies its own criteria for SMR, ASMR and the target population.
Five Theses on EU HTA and National HTA Processes: Why One JCA Requires Different National Evidence Strategies
The Joint Clinical Assessment (JCA) establishes a common European assessment of comparative clinical effectiveness and safety under the EU HTA Regulation. National HTA processes, however, remain decisive for subsequent appraisal, reimbursement and pricing. The first JCA reports and their implementation in Germany and France show that differences in PICO, comparators, endpoints, evidence methods and national evidence appraisal need to be considered early in evidence planning.
Donidalorsen (Dawnzera): Why garadacimab was not included in the appropriate comparator therapy
In the German benefit assessment of donidalorsen (marketed as Dawnzera), Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) found an indication of a minor added benefit versus berotralstat in its decision of 20 August 2026. For this hereditary angioedema (HAE) procedure, the G-BA determined routine prophylaxis with a C1 esterase inhibitor, lanadelumab or berotralstat as the appropriate comparator therapy (zweckmäßige Vergleichstherapie, ACT).
AMNOG 2.0: How Germany is debating the future of benefit assessment
AMNOG 2.0 refers to the ongoing debate on how Germany's early benefit assessment framework should evolve. Key issues include managing evidence uncertainty, assessing therapies in special clinical circumstances, reassessing medicines as new evidence emerges, and balancing the recognition of therapeutic innovation with healthcare affordability.
Real-World Evidence in the AMNOG Dossier: Which Data Sources Can Robustly Define the Target Population?
Real-world evidence can support the German AMNOG dossier by informing epidemiological estimates, the statutory health insurance (GKV) target population, and the German healthcare context. Relevant sources include national registries, patient registries, epidemiological studies, and German claims data. The German Health Research Data Centre (Forschungsdatenzentrum Gesundheit, FDZ) adds a cross-insurer source of GKV routine data.
AMNOG analyses: How to manage thousands of GBA tables efficiently and reliably
AMNOG dossiers can require thousands of statistical tables. Reproducible analysis workflows help generate GBA outputs consistently, implement changes in a controlled manner, and produce German and English tables from a common analytical process.
EU HTA in Germany: What JCA means for AMNOG and the Delta-Dossier
Since January 2025, the EU HTA Regulation has become progressively relevant for the joint clinical assessment of new medicines. With the Joint Clinical Assessment, a common European evidence base is being established to support national HTA procedures and reduce duplication of work. For Germany, however, this does not mean that the AMNOG procedure will be replaced.
Tovorafenib after the JCA: What the first G-BA benefit assessment reveals about the EU-to-Germany evidence transfer
The first German benefit assessment of a medicinal product following a Joint Clinical Assessment shows concrete differences between the European and national evaluation of clinical evidence. In the case of tovorafenib, these differences primarily concern comparative evidence, the patient relevance of endpoints, the data cuts used, and the timing of the JCA report. The case therefore confirms a central point for the delta dossier: the delta dossier is not an official regulatory term, but a working term used in the German market access context for the national content and adaptations required between the JCA dossier and the AMNOG dossier.
Statutory Health Insurance Contribution Stabilization Act: Implications for AMNOG, Market Access and Dossier Strategy
Germany's Statutory Health Insurance Contribution Stabilization Act (GKV-Beitragssatzstabilisierungsgesetz), adopted in July 2026, expands the economic controls applied to innovative medicines. The Act introduces higher statutory manufacturer discounts, stronger price-volume arrangements and rebate contracts for patent-protected products. It does not abolish Germany's, the national and reimbursement process for newly authorised medicines. It changes how the result of that assessment is translated into realised commercial value.
Joint Clinical Assessment: What the First Four JCA Reports Reveal About Evidence Assessment
The first four published Joint Clinical Assessment (JCA) reports reveal recurring methodological challenges in European evidence assessment. Key issues include PICO scoping and comparators, indirect treatment comparisons, the selection of prognostic factors and effect modifiers, and the handling of non-randomised evidence and post-hoc analyses. For manufacturers, the critical question is therefore whether the evidence for each PICO can be planned, generated and presented in a methodologically robust and transparent way.
Discontinued JCAs: Why Joint Clinical Assessments are discontinued
Joint Clinical Assessments can be discontinued for different reasons. The cases reviewed to date show two main scenarios: the underlying EMA marketing authorisation application is withdrawn, or the JCA dossier does not meet key requirements for completeness, methodology, transparency and documentation. The cases of Zumrad / sasanlimab, catequentinib, Tacquell and sintilimab illustrate the different reasons why a JCA procedure may not be completed.
EU JCA and national HTA: Where methodological differences begin after the JCA
The Joint Clinical Assessment harmonizes parts of clinical evidence assessment across Europe, but it does not harmonize all methodological requirements of national HTA processes. A comparative analysis of EU HTAR and HTA systems in Germany, France, the Netherlands and Spain identifies common ground in core evidence standards, alongside relevant differences in scoping, indirect comparisons, non-randomized evidence and the handling of uncertainty.
Five theses on the Delta-Dossier: Why Germany needs more than cross-references
The term Delta-Dossier is not an official regulatory term. In the German market-access context, it describes the national adaptation required to use content from the European JCA dossier in the AMNOG process and to supplement it with Germany-specific content, analyses and evidence.
Real-World Evidence in the EU-JCA: Where RWE Can Close Evidence Gaps and Where Its Limits Lie
Real-world evidence can contribute far more to the EU Joint Clinical Assessment than describing epidemiology and treatment patterns. RWE can support PICO scoping, identify prognostic factors and effect modifiers, enable external control arms, and provide additional information for evidence synthesis. At the same time, broader use of RWE increases the methodological requirements for data quality, confounding control, comparability, and analytical justification.